Shareholdings
| Concept | As at 2024-12-31 | As at 2023-12-31 | 
|---|---|---|
| Shareholdings | ||
| Largest holding company | ||
| Details of specified investment shares held for purposes other than pure investment | ||
| Issue | 
                                                Centassa Pharmaceuticals PLC
                                                
                                             | — | 
| Number of shares | 
                                                929,353
                                                
                                                    
                                                        xbrli:shares
                                                    
                                                
                                             | 
                                                929,353
                                                
                                                    
                                                        xbrli:shares
                                                    
                                                
                                             | 
| Carrying amount | 
                                                2,441,000,000
                                                
                                                    
                                                        JPY
                                                    
                                                
                                             | 
                                                1,043,000,000
                                                
                                                    
                                                        JPY
                                                    
                                                
                                             | 
| Purpose of shareholding, overview of business alliance, quantitative effects of shareholding and reason for increase in number of shares | 
                                                オレキシン受容体のポジティブモジュレーター及び類縁薬に対するNxera Pharma UK Limitedが所有するノウハウ等の権利を許諾しております。取得した対価の価値が当該開発進捗の成果を反映して最大化することを目的として保有しております。
                                                
                                             | — | 
| Whether issuer of aforementioned shares holds reporting company's shares | 
                                                無
                                                
                                             | — |